Glucagon

Approved source records

1. Authors response to the comments by Muhammad Salman, Muhammad Hammad Chola and Muhammad Hasan on our paper "prescribing patterns of glucagon like peptide-1 receptor agonists in the Swedish capital region: a register-based cross-sectional study".

   DOI: 10.1007/s00228-026-04056-0PMID: 42036553

   Source identity and connection checked by Codex (AI).

2. Cardiometabolic Effects of Dual GLP-1 and Glucagon Receptor Agonists: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

   DOI: 10.2337/dc26-1127PMID: 42627353

   Source identity and connection checked by Codex (AI).

3. Comment on "Prescribing patterns of glucagon like peptide-1 receptor agonists in the Swedish capital region: a register-based cross-sectional study".

   DOI: 10.1007/s00228-026-04055-1PMID: 42036491

   Source identity and connection checked by Codex (AI).

4. Comment on: "Glucagon-Like Peptide-1 Receptor Agonists and Risk of Systemic and Ocular Vascular Complications in Patients With Type 2 Diabetes and Diabetic Retinopathy".

   DOI: 10.1016/j.ajo.2026.07.063PMID: 42632508

   Source identity and connection checked by Codex (AI).

5. Correction: Association of glucagon-like peptide-1 (GLP-1) receptor agonists and diabetic retinopathy (DR) - a systematic review and meta-analysis.

   DOI: 10.3389/fmed.2026.1778742PMID: 41728591

   Source identity and connection checked by Codex (AI).

6. Current Challenges in Monitoring the Safety and Utilisation of the Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs): A UK Perspective.

   DOI: 10.1007/s40264-026-01676-4PMID: 42086849

   Source identity and connection checked by Codex (AI).

7. Dysfunctional Lipid-Induced Secretion of Glucagon-Like Peptide-2(GLP-2), but Not of Incretins Glucagon-Like Peptide-1(GLP-1)/Glucose-Dependent Insulinotropic Polypeptide(GIP), Promotes Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Onset and Progression Through Gut Barrier Disruption and Endotoxemia.

   DOI: 10.1002/mco2.70323PMID: 41948456

   Source identity and connection checked by Codex (AI).

8. Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes : An Updated Systematic Review.

   DOI: 10.7326/annals-25-05519PMID: 42673585

   Source identity and connection checked by Codex (AI).

9. Efficacy and safety of glucagon-like peptide-1 (GLP-1) agonists in pediatric obesity: A systematic review and meta-analysis.

   DOI: 10.4103/sjg.sjg_455_25PMID: 41848415

   Source identity and connection checked by Codex (AI).

10. Evidence on glucagon-like peptide-1 receptor agonists around conception: cautious interpretation (reply to letter to the editor).

    DOI: 10.1016/j.ajog.2026.07.012PMID: 42462797

    Source identity and connection checked by Codex (AI).

11. Glucagon like Peptide-1 (GLP‑1) receptor agonists: There is no such thing as a free lunch.

    DOI: 10.1016/j.amjmed.2026.02.026PMID: 41785948

    Source identity and connection checked by Codex (AI).

12. Glucagon-Like Peptide 1 Receptor Agonist Use and Vertebral Fracture Risk in Type 2 Diabetes.

    DOI: 10.1001/jamasurg.2025.5372PMID: 41369924

    Source identity and connection checked by Codex (AI).

13. Glucagon-Like Peptide-1 Receptor Agonists and Cancer-Reply.

    DOI: 10.1001/jamaoncol.2025.5370PMID: 41410912

    Source identity and connection checked by Codex (AI).

14. Glucagon-Like Peptide-1 Receptor Agonists and Cancer.

    DOI: 10.1001/jamaoncol.2025.5364PMID: 41411009

    Source identity and connection checked by Codex (AI).

15. Glucagon-Like Peptide-1 Receptor Agonists and Cancer.

    DOI: 10.1001/jamaoncol.2025.5367PMID: 41410932

    Source identity and connection checked by Codex (AI).

16. Glucagon-like peptide-1 receptor agonists & thyroid cancer: What thyroid surgeons should know.

    DOI: 10.1016/j.amjsurg.2026.116975PMID: 41990629

    Source identity and connection checked by Codex (AI).

17. Glucagon-like peptide-1 receptor agonists and cognitive function: beyond the metabolic effects.

    DOI: 10.1007/s42000-026-00827-7PMID: 42736531

    Source identity and connection checked by Codex (AI).

18. Glucagon-like peptide-1 receptor agonists in pediatrics: The pancreatology perspective.

    DOI: 10.1002/jpn3.70512PMID: 42535519

    Source identity and connection checked by Codex (AI).

19. Highly selective SGLT2 inhibitors suppress glucose uptake in alpha-TC1 cells, while glucagon secretion is not affected.

    DOI: 10.1007/s42000-026-00805-zPMID: 42420684

    Source identity and connection checked by Codex (AI).

20. Inadvertent glucagon-like peptide-1 receptor agonist exposure in pregnancy: reassuring data, unresolved safety (letter to the editor).

    DOI: 10.1016/j.ajog.2026.07.011PMID: 42462798

    Source identity and connection checked by Codex (AI).

21. Medication holds and extended fasting in patients on glucagon-like peptide-1 receptor agonists: interpreting evidence when practice is already ahead of data.

    DOI: 10.1007/s12630-026-03185-5PMID: 42618721

    Source identity and connection checked by Codex (AI).

22. Modeling and analyzing glucose-insulin interactions during diabetes through fractional dynamics in presence of glucagon.

    DOI: 10.1016/j.jare.2026.01.020PMID: 41544758

    Source identity and connection checked by Codex (AI).

23. Pre-operative gastric volume measurement and glucagon-like peptide-1 receptor agonists.

    DOI: 10.1111/anae.70293PMID: 42429195

    Source identity and connection checked by Codex (AI).

24. Psychiatric and eye disorders associated with use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs).

    DOI: 10.1007/s00210-026-05813-9PMID: 42629417

    Source identity and connection checked by Codex (AI).

25. Putting a Glucagon-Like Peptide-1 Receptor Agonist Trial for Type 2 Diabetes in Context.

    DOI: 10.1001/jamanetworkopen.2026.15634PMID: 42234432

    Source identity and connection checked by Codex (AI).

26. Reply to Comment on: "Glucagon-like peptide-1 receptor agonists and risk of systemic and ocular vascular complications in patients with type 2 diabetes and diabetic retinopathy".

    DOI: 10.1016/j.ajo.2026.08.025PMID: 42636995

    Source identity and connection checked by Codex (AI).

27. Summary for Patients: An Updated Systematic Review on Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes.

    DOI: 10.7326/annals-25-05519-psPMID: 42673597

    Source identity and connection checked by Codex (AI).

28. Urological Complications of Morbid Obesity and the Role of Bariatric Surgery and Glucagon-Like Peptide-1 Receptor Agonists in Their Management: A Systematic Review.

    DOI: 10.7759/cureus.110952PMID: 42465136

    Source identity and connection checked by Codex (AI).

29. A Prospective Evaluation of Glucagon Stimulation Test Safety in Adults With Chronic Moderate-to-Severe Traumatic Brain Injury.

    2026

    DOI: 10.1002/edm2.70260PMID: 42298732

30. A non-enzymatic function of neuraminidase 1 restrains hepatic glucagon response in mice.

    2026

    DOI: 10.1038/s41467-026-72630-2PMID: 42091883

31. A simple mechanistic model for insulin-glucose-glucagon dynamics and its implications for diabetes management.

    2026

    DOI: 10.3934/mbe.2026060PMID: 42448581

32. Acute glucagon infusion induces natriuresis and diuresis through a direct tubular mechanism involving overlapping receptor pathways.

    2026

    DOI: 10.1152/ajprenal.00195.2026PMID: 42568245

33. Additive Glucagonotropic and Insulinotropic Effects of Glucose-Dependent Insulinotropic Polypeptide and Alanine in Fasted Healthy Men.

    2026

    DOI: 10.1111/dom.71273PMID: 42712058

34. Alpha-cell glucagon is essential for maintaining β-cell function and identity in adult mice.

    2026

    DOI: 10.1016/j.jbc.2026.113145PMID: 42134544

35. Altered Glucagon Response to Oral Glucose in Individuals at Different Stages of Type 1 Diabetes Development.

    2026

    DOI: 10.1210/clinem/dgaf601PMID: 41172278

36. Amino Acid Sensing by the α-Cell Mitochondrial Phosphoenolpyruvate Cycle Regulates Intracellular Ca2+ Levels Without Affecting Glucagon Secretion.

    2026

    DOI: 10.2337/db25-0510PMID: 41525135

37. Antecedent hypoglycaemia impairs glucagon secretion by enhancing somatostatin-mediated negative feedback control.

    2026

    DOI: 10.1038/s42255-025-01422-7PMID: 41530286

38. Association between glucagon and stroke in patients with type 2 diabetes.

    2026

    DOI: 10.1530/ec-25-0791PMID: 41648993

39. Association between sleep disorders and alterations in glucose metabolism, insulin, and glucagon in patients with type 2 diabetes.

    2026

    DOI: 10.1097/md.0000000000047409PMID: 41686553

40. Association of fasting plasma glucagon with osteopenia/osteoporosis in Chinese patients with type 2 diabetes.

    2026

    DOI: 10.1186/s12902-026-02220-2PMID: 41814251

41. Associations of Fasting Glucagon and the Glucagon-Alanine Index With Hepatic Steatosis and Liver Stiffness in Japanese Individuals With Type 2 Diabetes.

    2026

    DOI: 10.1111/dom.70854PMID: 42244477

42. Chronic Glycaemic Control Modulates the Relationship Between GIP and Glucagon Secretion Following Oral and Enteral Nutrients in Type 2 Diabetes.

    2026

    DOI: 10.1111/dom.70735PMID: 41943672

43. Conformational determinants of glucagon stability and aggregation kinetics in aqueous and commercial formulations.

    2026

    DOI: 10.1002/pro.70750PMID: 42557738

44. Differential Longitudinal Effects of Glucose-Lowering Medications on Glucagon and C-peptide Responses in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).

    2026

    DOI: 10.2337/dc25-2186PMID: 41432725

45. Distinctive patterns of glucagon and incretin responses to oral and isoglycaemic intravenous glucose load in fibrocalculous pancreatic diabetes.

    2026

    DOI: 10.1038/s41598-026-55406-yPMID: 42321243

46. Dose-Response Effect of Glucagon on Glucose, Beta-Cell Secretion and Metabolism in Healthy Individuals.

    2026

    DOI: 10.1111/dom.70896PMID: 42169368

47. Dysregulated glucagon signaling contributes to hypoglycemia after vertical sleeve gastrectomy in mice.

    2026

    DOI: 10.1016/j.molmet.2026.102399PMID: 42270043

48. EXPRESS: Comparing the Efficacy of Transmucosal and Subcutaneous Glucagon Administration in Response to Insulin-Induced Hypoglycemia in Healthy Cats.

    2026

    DOI: 10.1177/1098612x261471152PMID: 42444066

49. Early glucagon-positive cells restrict pancreatic branching through VMAT2-noradrenaline-mediated ROS signaling.

    2026

    DOI: 10.1242/dev.205734PMID: 42643105

50. Early loss and progressive deterioration of glucagon responses to hypoglycemia in children with type 1 diabetes.

    2026

    DOI: 10.1136/bmjdrc-2026-005959PMID: 42648789

51. Effect of somatostatin receptor 2 antagonism on glucagon counterregulation during a hyperinsulinaemic euglycaemic-hypoglycaemic glucose clamp in adult men and women with long-standing type 1 diabetes: a randomised crossover phase 1 study.

    2026

    DOI: 10.1007/s00125-026-06748-9PMID: 42168649

52. Effects of Pharmacological GIP Infusion on Insulin, Glucagon, and Cardiovascular Responses During Hyperglycemia in Type 2 Diabetes.

    2026

    DOI: 10.2337/db26-0267PMID: 42447284

53. Experimental chronic fetal hyperglucagonemia stimulates hepatic pathways for amino acid catabolism and gluconeogenesis.

    2026

    DOI: 10.1530/joe-25-0447PMID: 41988876

54. Glucagon and beta-cell function changes before and after dietary weight loss-induced metabolic improvements in type 2 diabetes.

    2026

    DOI: 10.1016/j.diabres.2026.113382PMID: 42341884

55. Glucagon and insulin prescribing trends and cost implications in Japan: a 10-year analysis using the National Database Open Data Japan.

    2026

    DOI: 10.1007/s13340-026-00880-yPMID: 41767683

56. Glucagon may be extracted across the liver by a glucagon receptor-dependent mechanism, and this is impaired in an animal model of fatty liver disease.

    2026

    DOI: 10.1152/ajpendo.00493.2025PMID: 41661080

57. Glucagon promotes net hepatic glycogen repletion following meal ingestion.

    2026

    DOI: 10.1172/jci.insight.201076PMID: 41774508

58. Glucagon receptor blockade protects spermatogenesis by enhancing PFKFB3-mediated lactate production in Sertoli cells.

    2026

    DOI: 10.1186/s12967-026-08588-yPMID: 42458466

59. Glucagon receptor deficiency is associated with glucocorticoid receptor activation and proteolytic remodeling in gastrocnemius of male mice.

    2026

    DOI: 10.1152/ajpendo.00076.2026PMID: 42572238

60. Glucagon receptor signaling is indispensable for the healthspan effects of caloric restriction in aging male mice.

    2026

    DOI: 10.1007/s11357-025-01899-wPMID: 40993467

61. Glucagon secretion by pancreatic alpha-cells requires an intact tubulin-cytoskeleton-primary cilium axis.

    2026

    DOI: 10.1186/s10020-026-01428-1PMID: 41667949

62. Glucagon-stimulated copeptin response in children: a proof-of-concept study.

    2026

    DOI: 10.3389/fendo.2026.1833629PMID: 42369064

63. Hepatic steatosis in humans is associated with preserved glucagon action on amino acid metabolism.

    2026

    DOI: 10.1172/jci200913PMID: 41433112

64. Identification of insulin and glucagon genes in the finless porpoise and the developmental distribution of their producing endocrine cells.

    2026

    DOI: 10.3389/fendo.2026.1777351PMID: 42147104

65. Improved Glucagon Sensitivity Following Weight Loss: A Systematic Review and Meta-Analysis.

    2026

    DOI: 10.1111/obr.70167PMID: 42152601

66. In vivo dysregulation of insulin and glucagon secretion: Disturbed mitochonderial VDAC1 expression and localization in pancreatic β-cells convey global insulin secretory defects in diabetic GK rat.

    2026

    DOI: 10.1016/j.bbadis.2026.168358PMID: 42402267

67. Increased Early Postprandial Glucagon Concentrations in Humans With Newly Diagnosed Type 2 Diabetes and Steatotic Liver Disease.

    2026

    DOI: 10.2337/dc25-3077PMID: 41931030

68. Incretin and Glucagon Signalling in MASLD and MASH: Integrating Metabolic Pathways With Disease Progression.

    2026

    DOI: 10.1111/dom.70624PMID: 41816810

69. Integrated Experimental and Molecular Modeling Techniques to Investigate the Buffer Effects on Glucagon Stability.

    2026

    DOI: 10.1007/s11095-026-04022-6PMID: 41792504

70. Integrated glucagon model for estimation of α-cell responsivity to glucose and amino acids during graded glucose infusion.

    2026

    DOI: 10.1152/ajpendo.00389.2025PMID: 41818159

71. Intra-Islet Paracrine Regulation of Glucagon Secretion During Hypoglycemia, Euglycemia, and Hyperglycemia.

    2026

    DOI: 10.1111/nyas.70384PMID: 42734243

72. Intravenous Glucagon Infusion in the Management of Hypoglycemia in Infants of Diabetic Mothers.

    2026

    DOI: 10.1055/a-2788-2020PMID: 41610862

73. Liver fibrosis and type 2 diabetes modulate postprandial incretin and glucagon responses in fatty liver disease.

    2026

    DOI: 10.1007/s13105-026-01141-xPMID: 41649634

74. Loss of Slc39a5 in α-cells impairs glucose metabolism by chronically increasing glucagon.

    2026

    DOI: 10.1016/j.jare.2025.11.013PMID: 41223989

75. Loss of α-cell GRK2 modulates glucagon response and supports cardiac function.

    2026

    DOI: 10.1016/j.molpha.2026.100115PMID: 41895229

76. Lower glucagon response and attenuated hepatic glucagon signaling in MASLD.

    2026

    DOI: 10.1016/j.diabet.2026.101787PMID: 42580550

77. Mitochondrial NCLX couples glucagon- and PDE2A-dependent signals to regulate hepatic lipid metabolism.

    2026

    DOI: 10.1016/j.molmet.2026.102433PMID: 42641876

78. Morning glucagon disrupts insulin induced hepatic metabolic memory and subsequent afternoon glucose metabolism in canines.

    2026

    DOI: 10.3389/fendo.2026.1832065PMID: 42137354

79. One Week Exposure to a Somatostatin Receptor 2 Antagonist (SSTR2a) Enhances Glucagon Counterregulation to Insulin-Induced Hypoglycaemia and Does Not Worsen Glycemia in a Male Rat Model of Insulin-Requiring Type 2 Diabetes.

    2026

    DOI: 10.1111/dom.71012PMID: 42315494

80. Pancreatic α-cell sodium-glucose cotransporter 1 (SGLT1) does not appear to contribute to hyperglucagonemia and glucose intolerance in diabetic mice.

    2026

    DOI: 10.1507/endocrj.ej25-0403PMID: 41371691

81. Paracrine inhibition via G protein inwardly rectifying potassium channels regulates glucagon secretion from human pancreatic alpha cells.

    2026

    DOI: 10.1016/j.celrep.2026.117068PMID: 41824458

82. Partial restoration of counterregulatory circulating glucagon by dapagliflozin and low-dose glibenclamide in men with type 1 diabetes: in vitro studies and randomised clinical crossover trial.

    2026

    DOI: 10.1016/j.ebiom.2026.106298PMID: 42155411

83. Postprandial Glucagon Action in the Human Brain.

    2026

    DOI: 10.1111/dom.70801PMID: 42017287

84. Postprandial Glucagon Metabolism in Healthy and Type 1 Diabetes.

    2026

    DOI: 10.2337/db25-0587PMID: 41264412

85. Prolonged Somatostatin Receptor 2 Antagonism Enhances Glucagon Response to Hypoglycemia in Male Diabetic Rats.

    2026

    DOI: 10.1210/endocr/bqaf192PMID: 41502124

86. Prostate T2-weighted spin-echo MRI with and without glucagon: a paired scan quality assessment.

    2026

    DOI: 10.1007/s00261-025-05215-0PMID: 41081882

87. Role of glucagon in metabolic diseases.

    2026

    DOI: 10.1111/jdi.70416PMID: 42593182

88. SEL1L-HRD1 ER-associated degradation facilitates prohormone convertase 2 maturation and glucagon production in islet α cells.

    2026

    DOI: 10.1038/s41467-026-69928-6PMID: 41741474

89. Sodium-glucose cotransporter-specific substrate αMG stimulates endogenous glucagon secretion and ameliorates obesity-associated metabolic disorders in mice.

    2026

    DOI: 10.1016/j.molmet.2026.102324PMID: 41619806

90. Somatostatin Receptor PET/CT in a Glucagonoma Presenting With Necrolytic Migratory Erythema and Normoglucagonemia: A Diagnostic Dilemma.

    2026

    DOI: 10.1097/rlu.0000000000006259PMID: 41937553

91. Somatostatin receptors shape insulin and glucagon output within the pancreatic islet in mice through direct and paracrine effects.

    2026

    DOI: 10.1007/s00125-026-06769-4PMID: 42322376

92. Specific Glucagon Assay System Using a Receptor-Derived Glucagon-Binding Peptide Probe.

    2026

    DOI: 10.3390/ijms27010515PMID: 41516388

93. Stathmin-2 mediates paracrine hormone regulation of glucagon through lysosomal trafficking in αTC1-6 cells.

    2026

    DOI: 10.1113/jp291537PMID: 42625306

94. TRPM7 kinase regulates α-cell proliferation and glucagon production in mice.

    2026

    DOI: 10.1016/j.molmet.2026.102317PMID: 41520832

95. Targeting glucagon signaling in metabolic disorders, functional insights from zebrafish receptor knockouts.

    2026

    DOI: 10.1007/s00018-026-06275-1PMID: 42332291

96. The ApoA-IV-LRP1 Signaling Axis: A Novel Insulin-Independent Pathway for the Suppression of Diabetic Hyperglucagonemia.

    2026

    DOI: 10.3390/cells15131229PMID: 42439702

97. The Glucagonocentric Basis of Diabetic Cardiomyopathy: Pancreas-Heart Crosstalk Linking α-Cell Dysregulation to Cardiac Metabolic Stress and Fibrosis.

    2026

    DOI: 10.1002/cph4.70145PMID: 41947455

98. The Glucagonotropic Effect of GIP Is Negated During Insulin-Induced Hypoglycemia in Type 1 Diabetes: A Randomized, Placebo-Controlled, Crossover Study.

    2026

    DOI: 10.2337/db25-1128PMID: 42085567

99. The bile acid-sensive ion channel (BASIC) is expressed in pancreatic α-cells and involved in glucagon secretion.

    2026

    DOI: 10.1007/s00424-026-03199-4PMID: 42521859

100. The expanding landscape of the glucagon signaling network: mechanisms and outcomes.

     2026

     DOI: 10.1210/endocr/bqag041PMID: 41926708

101. Twelve weeks of voluntary wheel running restores glucagon sensitivity in middle-aged mice.

     2026

     DOI: 10.1152/ajpendo.00244.2025PMID: 41494661

102. Uncoupling Insulin Sensitivity From Longevity: A Sex-Dependent Effect of Hepatic Glucagon Signaling.

     2026

     DOI: 10.1111/acel.70349PMID: 41482628

103. Unequal distribution of plasma glucagon levels among clustering-based diabetes subtypes: a Japanese cohort.

     2026

     DOI: 10.1210/clinem/dgaf654PMID: 41388999

104. Whey Protein Ingestion Stimulates Glucagon Secretion and Raises Blood Glucose Levels in Adults With Type 1 Diabetes.

     2026

     DOI: 10.2337/db26-0059PMID: 42030105

105. eNAMPT induces alpha-cell mass expansion but impaired glucagon counter regulatory response.

     2026

     DOI: 10.1210/endocr/bqag061PMID: 42271608

106. α-cell SLC38A5 supports amino acid-induced α-cell proliferation and glucagon secretion.

     2026

     DOI: 10.3389/fendo.2026.1830329PMID: 42375320

107. Augmented glucagon-induced gluconeogenesis in primary hepatocytes from Otsuka Long-Evans Tokushima Fatty rats.

     2025

     DOI: 10.1093/bbb/zbaf133PMID: 40928465

108. Contractile Effects of Glucagon in Mouse Cardiac Preparations.

     2025

     DOI: 10.3390/ijms27010126PMID: 41516006

109. Engineering Glucagon via Molecular and Formulation Strategies: From Natural Hormone to Effective and Stable Therapeutics.

     2025

     DOI: 10.1002/cbic.202500270PMID: 40459429

110. Fasting glucagon as an independent risk indicator for CAD in patient with type 2 diabetes.

     2025

     DOI: 10.3389/fendo.2025.1749418PMID: 41458542

111. Glucagon acutely stimulates hepatic gluconeogenesis.

     2025

     DOI: 10.1016/j.peptides.2025.171448PMID: 41093268

112. Glucagon in Pediatric Metabolic Disorders: Pathophysiology and Therapeutic Perspectives.

     2025

     DOI: 10.3390/pediatric17050104PMID: 41149695

113. Glucagon increases plasma levels of cyclic AMP responses in mice and humans, and this may be independent of MASLD.

     2025

     DOI: 10.1152/ajpendo.00296.2025PMID: 40983348

114. Glucagon, the Alpha Cell, and Potential Targets for Diabetes Treatment.

     2025

     DOI: 10.1210/endocr/bqaf162PMID: 41206016

115. Glucose-Dependent Insulinotropic Polypeptide and Glucagon After Weight Loss Induced by Diet or Bariatric Surgery.

     2025

     DOI: 10.1002/oby.70049PMID: 41024443

116. Impaired Glucagon Suppression Accompanied by Liver Fat Accumulation Mediated Worse Blood Glucose Control in Patients With T2D.

     2025

     DOI: 10.1210/clinem/dgaf303PMID: 40406971

117. Metabolic Effects of Glucagon Stimulations in Type 1 Diabetes and Healthy Controls.

     2025

     DOI: 10.1210/clinem/dgaf030PMID: 39829147

118. Metabolic and Paracrine Heterogeneity of Pancreatic Glucagon-Secreting α-Cells.

     2025

     DOI: 10.2337/db24-1053PMID: 40184031

119. Modeling the effect of glucagon on endogenous glucose production in healthy individuals under meal-like conditions.

     2025

     DOI: 10.1152/ajpregu.00172.2025PMID: 41187984

120. Nonlinear Mixed Effects Modeling of Glucagon Kinetics Assessed Using [<sup>13</sup>C<sup>15</sup>N]-Glucagon in Individuals With and Without Type 1 Diabetes.

     2025

     DOI: 10.1109/embc58623.2025.11254301PMID: 41336693

121. Prolonged glucagon exposure rewires lipid oxidation and drives diabetic kidney disease progression.

     2025

     DOI: 10.1038/s41467-025-63529-5PMID: 41022721

122. Splanchnic and Leg Glucagon Metabolism in Healthy Individuals and Those With Type 1 Diabetes: First-in-Human Study Using [13C9,15N1]Glucagon.

     2025

     DOI: 10.2337/db24-1064PMID: 40445879

123. Using glucagon receptor antagonism to evaluate the physiological effects of extrapancreatic glucagon in totally pancreatectomised individuals: a randomised controlled trial.

     2025

     DOI: 10.1007/s00125-025-06534-zPMID: 40968190

124. Intra-islet α-cell Gs signaling promotes glucagon release.

     2024

     DOI: 10.1038/s41467-024-49537-xPMID: 38879678

125. Glucagon Receptor Signaling and Glucagon Resistance

     2019

     DOI: 10.3390/ijms20133314PMID: 31284506

126. Glucagon Receptor Signaling and Lipid Metabolism

     2019

     DOI: 10.3389/fphys.2019.00413PMID: 31068828

127. Insulin Secretion Depends on Intra-islet Glucagon Signaling

     2018

     DOI: 10.1016/j.celrep.2018.10.018PMID: 30380405

128. Structure of the glucagon receptor in complex with a glucagon analogue

     2018

     DOI: 10.1038/nature25153PMID: 29300013

129. The New Biology and Pharmacology of Glucagon

     2017

     DOI: 10.1152/physrev.00025.2016PMID: 28275047

130. cAMP signalling in insulin and glucagon secretion

     2017

     DOI: 10.1111/dom.12993PMID: 28466587

131. Insulin Resistance Is Accompanied by Increased Fasting Glucagon and Delayed Glucagon Suppression in Individuals With Normal and Impaired Glucose Regulation

     2016

     DOI: 10.2337/db16-0240PMID: 27504013

132. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion

     2015

     DOI: 10.1038/nm.3828PMID: 25894829

133. Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP

     2013

     DOI: 10.1038/nature11808PMID: 23292513

134. Structure of the human glucagon class B G-protein-coupled receptor

     2013

     DOI: 10.1038/nature12393PMID: 23863937

135. Minireview: Glucagon in the Pathogenesis of Hypoglycemia and Hyperglycemia in Diabetes

     2011

     DOI: 10.1210/en.2011-1499PMID: 22166985

136. Physiologic action of glucagon on liver glucose metabolism

     2011

     DOI: 10.1111/j.1463-1326.2011.01454.xPMID: 21824265

137. The metabolic actions of glucagon revisited

     2010

     DOI: 10.1038/nrendo.2010.187PMID: 20957001

138. Insulin Signaling in α Cells Modulates Glucagon Secretion In Vivo

     2009

     DOI: 10.1016/j.cmet.2009.02.007PMID: 19356716

139. Physiology of the pancreatic α-cell and glucagon secretion: role in glucose homeostasis and diabetes

     2008

     DOI: 10.1677/joe-08-0290PMID: 18669612

140. The Glucagon Receptor Is Required for the Adaptive Metabolic Response to Fasting

     2008

     DOI: 10.1016/j.cmet.2008.09.008PMID: 19046568

141. Human adipose tissue-derived mesenchymal stem cells differentiate into insulin, somatostatin, and glucagon expressing cells

     2006

     DOI: 10.1016/j.bbrc.2006.01.072PMID: 16460677

142. Pancreatic signals controlling food intake; insulin, glucagon and amylin

     2006

     DOI: 10.1098/rstb.2006.1858PMID: 16815800

143. Inhibition of Dipeptidyl Peptidase-4 Reduces Glycemia, Sustains Insulin Levels, and Reduces Glucagon Levels in Type 2 Diabetes

     2004

     DOI: 10.1210/jc.2003-031907PMID: 15126524

144. Glucagon and regulation of glucose metabolism

     2003

     DOI: 10.1152/ajpendo.00492.2002PMID: 12626323

145. International Union of Pharmacology. XXXV. The Glucagon Receptor Family

     2003

     DOI: 10.1124/pr.55.1.6PMID: 12615957

146. Islet β-cell secretion determines glucagon release from neighbouring α-cells

     2003

     DOI: 10.1038/ncb951PMID: 12640462

147. Lower blood glucose, hyperglucagonemia, and pancreatic α cell hyperplasia in glucagon receptor knockout mice

     2003

     DOI: 10.1073/pnas.0237106100PMID: 12552113

148. Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans

     2001

     DOI: 10.1007/s001250100006PMID: 11719833

149. Adult insulin- and glucagon-producing cells differentiate from two independent cell lineages

     2000

     DOI: 10.1242/dev.127.11.2317PMID: 10804174

150. Lack of Suppression of Glucagon Contributes to Postprandial Hyperglycemia in Subjects with Type 2 Diabetes Mellitus1

     2000

     DOI: 10.1210/jcem.85.11.6993PMID: 11095432

151. The Origin and Function of the Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP)/Glucagon Superfamily*

     2000

     DOI: 10.1210/edrv.21.6.0414PMID: 11133067

152. Pax6 is required for differentiation of glucagon-producing α-cells in mouse pancreas

     1997

     DOI: 10.1038/387406a0PMID: 9163426

153. Expression cloning and signaling properties of the rat glucagon receptor

     1993

     DOI: 10.1126/science.8384375PMID: 8384375

154. Glucose-inhibition of glucagon secretion involves activation of GABAA-receptor chloride channels

     1989

     DOI: 10.1038/341233a0PMID: 2550826

155. Glucagon gene expression in vertebrate brain.

     1988

     DOI: 10.1016/s0021-9258(18)68261-4PMID: 2901414

156. Activation of two signal-transduction systems in hepatocytes by glucagon

     1986

     DOI: 10.1038/323068a0PMID: 3018586

157. Glucagon physiology and pathophysiology in the light of new advances

     1985

     DOI: 10.1007/bf00281991PMID: 3902546

158. Insulin within islets is a physiologic glucagon release inhibitor.

     1984

     DOI: 10.1172/jci111658PMID: 6392344

159. Conformation of glucagon in a lipid-water interphase by 1H nuclear magnetic resonance

     1983

     DOI: 10.1016/s0022-2836(83)80143-0PMID: 6631957

160. Hamster preproglucagon contains the sequence of glucagon and two related peptides

     1983

     DOI: 10.1038/302716a0PMID: 6835407

161. Glucagon and the a Cell

     1981

     DOI: 10.1056/nejm198106183042504PMID: 7015132

162. Role of Glucagon, Catecholamines, and Growth Hormone in Human Glucose Counterregulation

     1979

     DOI: 10.1172/jci109464PMID: 36413

163. C-peptide Response to Glucagon: A Test for the Residual β-cell Function in Diabetes Mellitus

     1977

     DOI: 10.2337/diab.26.7.605PMID: 326604

164. EFFECTS OF INSULIN, GLUCAGON, AND INSULIN/GLUCAGON INFUSIONS ON LIVER MORPHOLOGY AND CELL DIVISION AFTER COMPLETE PORTACAVAL SHUNT IN DOGS

     1976

     DOI: 10.1016/s0140-6736(76)90477-3PMID: 56646

165. INSULIN, GLUCAGON, AMINOACID IMBALANCE, AND HEPATIC ENCEPHALOPATHY

     1976

     DOI: 10.1016/s0140-6736(76)90541-9PMID: 62115

166. Physiology and pathophysiology of glucagon

     1976

     DOI: 10.1152/physrev.1976.56.4.778PMID: 185634

167. Regulation of Pancreatic Insulin and Glucagon Secretion

     1976

     DOI: 10.1146/annurev.ph.38.030176.002033PMID: 769657

168. Glucagon and plasma catecholamine responses to graded and prolonged exercise in man

     1975

     DOI: 10.1152/jappl.1975.38.1.70PMID: 1110246

169. Glucagon: Role in the Hyperglycemia of Diabetes Mellitus

     1975

     DOI: 10.1126/science.1089999PMID: 1089999

170. Regulation of hepatic regeneration in rats by synergistic action of insulin and glucagon.

     1975

     DOI: 10.1073/pnas.72.3.1157PMID: 1055372

171. THE ESSENTIAL ROLE OF GLUCAGON IN THE PATHOGENESIS OF DIABETES MELLITUS

     1975

     DOI: 10.1016/s0140-6736(75)92375-2PMID: 46337

172. X-ray analysis of glucagon and its relationship to receptor binding

     1975

     DOI: 10.1038/257751a0PMID: 171582

173. Lack of Glucagon Response to Hypoglycemia in Diabetes: Evidence for an Intrinsic Pancreatic Alpha Cell Defect

     1973

     DOI: 10.1126/science.182.4108.171PMID: 4581053

174. Glucagon-stimulating activity of 20 amino acids in dogs

     1972

     DOI: 10.1172/jci107046PMID: 4639019

175. Isolation from Porcine‐Intestinal Wall of a Vasoactive Octacosapeptide Related to Secretin and to Glucagon

     1972

     DOI: 10.1111/j.1432-1033.1972.tb01903.xPMID: 5069712

176. Effect of hypothalamic stimulation on plasma glucose, insulin, and glucagon levels

     1971

     DOI: 10.1152/ajplegacy.1971.221.6.1596PMID: 4941906

177. Glucagon Physiology and Pathophysiology

     1971

     DOI: 10.1056/nejm197108192850806PMID: 4997492

178. Glucagon and the Insulin:Glucagon Ratio in Diabetes and Other Catabolic Illnesses

     1971

     DOI: 10.2337/diab.20.12.834PMID: 5120326

179. Radioimmunological determination of pancreatic and gut glucagon in plasma

     1971

     DOI: 10.1007/bf02346248PMID: 5313395

180. The Glucagon-sensitive Adenyl Cyclase System in Plasma Membranes of Rat Liver

     1971

     DOI: 10.1016/s0021-9258(18)62389-0PMID: 4993962

181. The Glucagon-sensitive Adenyl Cyclase System in Plasma Membranes of Rat Liver

     1971

     DOI: 10.1016/s0021-9258(18)62390-7PMID: 4926550

182. The Glucagon-sensitive Adenyl Cyclase System in Plasma Membranes of Rat Liver

     1971

     DOI: 10.1016/s0021-9258(18)62032-0PMID: 4328442

183. The Glucagon-sensitive Adenyl Cyclase System in Plasma Membranes of Rat Liver

     1971

     DOI: 10.1016/s0021-9258(18)62386-5PMID: 4993961

184. The Glucagon-sensitive Adenyl Cyclase System in Plasma Membranes of Rat Liver

     1971

     DOI: 10.1016/s0021-9258(18)62388-9PMID: 4323237

185. The effect of experimental insulin deficiency on glucagon secretion

     1971

     DOI: 10.1172/jci106691PMID: 4935445

186. Glucagon levels and metabolic effects in fasting man

     1970

     DOI: 10.1172/jci106445PMID: 5480852

187. Pancreatic Glucagon Secretion in Normal and Diabetic Subjects

     1969

     DOI: 10.1097/00000441-196906000-00008PMID: 4893149

188. Cardiac Actions of Glucagon

     1968

     DOI: 10.1161/01.res.22.6.777PMID: 4385510

189. Cardiovascular Effects of Glucagon in Man

     1968

     DOI: 10.1056/nejm196807042790103PMID: 4872564

190. Glucagon

     1968

     DOI: 10.1161/01.res.22.6.789PMID: 5659816

191. Wick Chromatography for Rapid and Reliable Immunoassay of Insulin, Glucagon and Growth Hormone

     1968

     DOI: 10.1038/219193b0PMID: 5659651

192. INFLUENCE OF GLUCAGON, AN INDUCER OF CELLULAR AUTOPHAGY, ON SOME PHYSICAL PROPERTIES OF RAT LIVER LYSOSOMES

     1967

     DOI: 10.1083/jcb.33.2.437PMID: 4292315

193. PARTICIPATION OF LYSOSOMES IN CELLULAR AUTOPHAGY INDUCED IN RAT LIVER BY GLUCAGON

     1967

     DOI: 10.1083/jcb.35.2.c11PMID: 6055998

194. The Effects of Secretin, Pancreozymin, and Gastrin on Insulin and Glucagon Secretion in Anesthetized Dogs *

     1967

     DOI: 10.1172/jci105565PMID: 4290022

195. A Glucagon-Secreting Alpha-Cell Carcinoma of the Pancreas

     1966

     DOI: 10.1056/nejm196606232742503PMID: 4286757

196. Interrelationship of Glucagon, Insulin and Glucose: The Insulinogenic Effect of Glucagon

     1966

     DOI: 10.2337/diab.15.12.855PMID: 5957476

197. PROMOTION OF INSULIN SECRETION BY GLUCAGON

     1965

     DOI: 10.1016/s0140-6736(65)90761-0PMID: 14346763

198. THE EFFECTS OF TOTAL STARVATION UPON THE LEVELS OF CIRCULATING GLUCAGON AND INSULIN IN MAN*

     1963

     DOI: 10.1172/jci104788PMID: 13995385

199. Effect of Glucagon on the Metabolism of Adipose Tissue

     1961

     DOI: 10.1016/s0021-9258(18)64236-xPMID: 13710494

200. GLUCAGON ANTIBODIES AND AN IMMUNOASSAY FOR GLUCAGON*

     1961

     DOI: 10.1172/jci104357PMID: 13779204

201. STUDIES ON THE PHARMACOLOGY OF GLUCAGON

     1960

     DOI: 10.1016/s0022-3565(25)25785-8PMID: 13821530

202. Glucagon Antibodies and Their Use for Immunoassay for Glucagon.

     1959

     DOI: 10.3181/00379727-102-25338PMID: 13840405

203. THE RELATIONSHIP OF EPINEPHRINE AND GLUCAGON TO LIVER PHOSPHORYLASE

     1957

     DOI: 10.1016/s0021-9258(18)65045-8PMID: 13398422

204. THE RELATIONSHIP OF EPINEPHRINE AND GLUCAGON TO LIVER PHOSPHORYLASE

     1956

     DOI: 10.1016/s0021-9258(18)65911-3PMID: 13278355

205. THE RELATIONSHIP OF EPINEPHRINE AND GLUCAGON TO LIVER PHOSPHORYLASE

     1956

     DOI: 10.1016/s0021-9258(18)65909-5PMID: 13278353

206. THE RELATIONSHIP OF EPINEPHRINE AND GLUCAGON TO LIVER PHOSPHORYLASE

     1956

     DOI: 10.1016/s0021-9258(18)65910-1PMID: 13278354

207. PURIFICATION AND CRYSTALLIZATION OF GLUCAGON

     1955

     DOI: 10.1016/s0021-9258(18)70910-1PMID: 14381399